Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery

European Journal of Pharmacology

Volumn 650, Issue 2-3, 2011, Pages 605-611

  Yamazaki, Takanobu ^a   Anraku, Tsuyoshi ^a   Matsuzawa, Shigeki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

cAMP; Cerebral vasodilator; Ibudilast; Mixed phosphodiesterase (PDE) 3 4 inhibitor; NO cGMP signaling; Vertebrobasilar artery

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 9 (TETRAHYDRO 2 FURYL)ADENINE; CILOSTAMIDE; CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE INHIBITOR; IBUDILAST; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V INHIBITOR; ROLIPRAM; SEROTONIN; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTERY TONE; ARTICLE; BASILAR ARTERY; BRAIN ARTERY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENINE; ADENYLATE CYCLASE; ANIMALS; BASILAR ARTERY; CYCLIC GMP; GUANYLATE CYCLASE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PYRIDINES; RABBITS; SIGNAL TRANSDUCTION; VASODILATOR AGENTS; VERTEBRAL ARTERY;

EID: 78651100327     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.033     Document Type: Article

References (25)

1. W.M. Armstead, R. Mirro, C.W. Leffler, and D.W. Busija The role of prostanoids in the mediation of responses to KC-404, a novel cerebrovasodilator J. Pharmacol. Exp. Ther. 244 1988 138 143
2. O. Bartsch, B. Bartlick, and R. Ivell Phosphodiesterase 4 inhibition synergizes with relaxin signaling to promote decidualization of human endometrial stromal cells J. Clin. Endocrinol. Metab. 89 2004 324 334
3. S. Birk, L. Edvinsson, J. Olesen, and C. Kruuse Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries Eur. J. Pharmacol. 489 2004 93 100
4. A. Daugan, P. Grondin, C. Ruault, L. Monnier, A.C. de Gouville, H. Coste, J. Kirilovsky, F. Hyafil, and R. Labaudinière The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5, 6, 11, 11a-tetrahydro-1H-imidazo[1′, 5′:1, 6]pyrido[3, 4-b]indole-1, 3(2H)-dione analogues J. Med. Chem. 46 2003 4525 4532
5. L.C. Gibson, S.F. Hastings, I. McPhee, R.A. Clayton, C.E. Darroch, A. Mackenzie, F.L. Mackenzie, M. Nagasawa, P.A. Stevens, and S.J. Mackenzie The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family Eur. J. Pharmacol. 538 2006 39 42
6. Y. Kishi, S. Ohta, N. Kasuya, S. Sakita, T. Ashikaga, and M. Isobe Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall Cardiovasc. Drug Rev. 19 2001 215 225
7. C. Kruuse, T.S. Khurana, S.D. Rybalkin, S. Birk, U. Engel, L. Edvinsson, and J. Olesen Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig Eur. J. Pharmacol. 521 2005 105 114
8. C. Lugnier Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents Pharmacol. Ther. 109 2006 366 398
9. C. Lugnier, and N. Komas Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilation Eur. Heart J. 14 1993 141 148
10. C. Lugnier, T. Keravis, and A. Eckly-Michel Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel J. Physiol. Pharmacol. 50 1999 639 652
11. D.H. Maurice Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system Front. Biosci. 10 2005 1221 1228
12. T. Nakagomi, N.F. Kassell, T. Sasaki, R.M. Lehman, J.C. Torner, K. Hongo, and J.H. Lee Effect of removal of the endothelium on vasocontraction in canine and rabbit basilar arteries J. Neurosurg. 86 1988 757 766
13. T. Nakahara, M. Yunoki, H. Moriuchi, A. Mitani, K. Sakamoto, and K. Ishii Relaxation and potentiation of cGMP-mediated response by ibudilast in bovine tracheal smooth muscle Naunyn-Schmiedeberg's Arch. Pharmacol. 366 2002 262 269
14. M. Ohashi, J. Kito, and K. Nishino Mode of cerebral vasodilating action of KC-404 in isolated canine basilar artery Arch. Int. Pharmacodyn. Thér. 280 1986 216 229
15. H. Onoue, N. Kaito, S. Tokudome, T. Irikura, K. Okada, T. Abe, and N. Nakamura The potentiating effect of KC-404 on prostacyclin-induced vasodilation in isolated human cerebral artery Gen. Pharmacol. 23 1992 1093 1095
16. D.A. Pelligrino, and Q. Wang Cyclic nucleotide crosstalk and the regulation of cerebral vasodilation Prog. Neurobiol. 56 1998 1 18
17. T. Saeki, and I. Saito Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta Biochem. Pharmacol. 46 1993 833 839
18. P. Sandner, M. Kornfeld, X. Ruan, W.J. Arendshorst, and A. Kurtz Nitric oxide/cAMP interactions in the control of rat renal vascular resistance Circ. Res. 84 1999 186 192
19. S.I. Savitz, and L.R. Caplan Vertebrobasilar disease N Engl J. Med. 352 2005 2618 2626
20. T. Sudo, K. Tachibana, K. Toga, S. Tochizawa, Y. Inoue, Y. Kimura, and H. Hidaka Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity Biochem. Pharmacol. 59 2000 347 356
21. K. Takuma, E. Lee, R. Enomoto, K. Mori, A. Baba, and T. Matsuda Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model Br. J. Pharmacol. 133 2001 841 848
22. W.J. Thompson, and M.M. Appleman Multiple cyclic nucleotide phosphodiesterase activities from rat brain Biochem. 10 1971 311 316
23. T.J. Torphy, and L.B. Cieslinski Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle Mol. Pharmacol. 37 1990 206 214
24. R.N. Willette, A.O. Shiloh, C.F. Sauermelch, A. Sulpizio, M.P. Michell, L.B. Cieslinski, T.J. Torphy, and E.H. Ohlstein Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors J. Cereb. Blood Flow Metab. 17 1997 210 219
25. L.C. Wright, J. Seybold, A. Robichaud, I.M. Adcock, and P.J. Barnes Phosphodiesterase expression in human epithelial cells Am. J. Physiol. 275 1998 L694 L700